Dominari Holdings Inc. (NASDAQ:DOMH) Short Interest Update

Posted by Ed Jones on Mar 1st, 2025

Dominari Holdings Inc. (NASDAQ:DOMH – Get Free Report) saw a significant increase in short interest during the month of February. As of February 15th, there was short interest totalling 952,800 shares, an increase of 232.0% from the January 31st total of 287,000 shares. Based on an average daily volume of 1,480,000 shares, the days-to-cover ratio is currently 0.6 days. Approximately 30.6% of the shares of the company are short sold.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Dominari stock. Renaissance Technologies LLC raised its holdings in Dominari Holdings Inc. (NASDAQ:DOMH – Free Report) by 20.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 56,326 shares of the company’s stock after acquiring an additional 9,400 shares during the period. Renaissance Technologies LLC owned approximately 0.89% of Dominari worth $55,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 42.48% of the company’s stock.

Dominari Trading Up 0.4 %

Shares of Dominari stock traded up $0.03 during trading hours on Friday, reaching $7.80. The stock had a trading volume of 268,952 shares, compared to its average volume of 2,458,745. The stock’s 50 day moving average is $3.94 and its 200 day moving average is $2.49. The firm has a market capitalization of $49.42 million, a PE ratio of -2.02 and a beta of 1.25. Dominari has a twelve month low of $0.83 and a twelve month high of $13.58.

Dominari Dividend Announcement

The business also recently declared a dividend, which will be paid on Monday, March 3rd. Investors of record on Monday, February 24th will be given a dividend of $0.32 per share. The ex-dividend date is Monday, February 24th.

Dominari Company Profile

(Get Free Report)

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.